Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
PULSE BIOSCIENCES insider transactions: Darrin Uecker, Chief Technology Officer and director, executed option exercises and sales under a Rule 10b5-1 plan adopted June 12, 2025. On 09/11/2025, 09/12/2025 and 09/15/2025 he exercised three separate $4 stock option tranches of 25,000 shares each and contemporaneously sold 25,000 shares on each date. The reported weighted-average sale prices ranged by date: $14.41–$15.14 (09/11 weighted $14.78), $13.80–$14.76 (09/12 weighted $14.32), and $15.18–$17.20 (09/15 weighted $15.77). Following the transactions the filings show beneficial ownership positions reported in the Form 4 tables (e.g., 122,872 shares on the non-derivative table after sales). The options became fully vested on September 8, 2019 per the employment agreement.
Pulse Biosciences (PLSE) reported a Form 144 notice showing a proposed sale of 120,000 common shares by means of a broker, with an aggregate market value of $1,772,400 and an approximate sale date of 09/11/2025 on NASDAQ. The filing states the shares were acquired and paid for on 09/11/2025 through the exercise of stock options issued by the company, with payment made in cash. The broker listed is Morgan Stanley Smith Barney LLC. The filer also disclosed two prior open-market sales by the same person in June 2025 totaling 30,000 shares for gross proceeds of $485,700. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Pulse Biosciences announced FDA approval of an Investigational Device Exemption (IDE) to begin a clinical study of its nsPFA Cardiac Surgical System for treating atrial fibrillation (AF). The approved NANOCLAMP AF study is a single-arm, prospective trial designed to show primary effectiveness when used in concomitant cardiac surgery. Up to 20 sites (including two outside the U.S.) are planned to enroll as many as 136 patients. The filing attaches a company press release and reiterates standard forward-looking statement cautions about clinical, regulatory, and technological risks.
Pulse Biosciences announced the enrollment of the first patients in a multicenter, IRB-approved study (PRECISE) evaluating its nsPFA™ Percutaneous Electrode System to treat benign thyroid nodules (BTNs). The filing states the press release dated September 2, 2025, confirms successful initial procedures and that the release is attached as Exhibit 99.1.
The company describes the study as multicenter and IRB-approved, indicating clinical development progress for its proprietary nsPFA technology in a new indication. No financial results, timelines for completion, patient numbers beyond “first patients,” or efficacy/safety data are included in the filing.
Pulse Biosciences announced publication of early clinical data from a first-in-human, single-arm feasibility study of its CellFX nsPFA Percutaneous Electrode System to treat benign thyroid nodules. The study, conducted at a single center in Naples, Italy, used ultrasound-guided ablation for tissue-response assessments and therapeutic intent. Follow-up ultrasounds showed no intranodular fibrosis or scarring. Fully treated nodules had an average 86% reduction in size at one year, with individual reductions up to 93%, and patients experienced symptom relief with reductions greater than 48% as early as two weeks. The company attached the related press release as an exhibit.
Richard van den Broek, a director of Pulse Biosciences, was granted a stock option on 08/15/2025 to purchase 30,000 shares of common stock at an exercise price of $16.16 per share. The option becomes exercisable beginning 08/15/2025 and expires 08/15/2035. The shares subject to the option vest in equal monthly installments over one year, with the first installment on 09/15/2025, contingent on continued service.
Mahkam Zanganeh, a director of Pulse Biosciences (PLSE), reported receipt of two stock option grants on 08/15/2025 totaling 54,134 options. Both options have an exercise price of $16.16 and expire on 08/15/2035. The first option covers 30,000 shares and vests in equal monthly installments over one year beginning 09/15/2025. The second covers 24,134 shares and vests in equal quarterly installments over one year beginning 09/05/2025. Ownership after the transactions is reported as 30,000 and 24,134 shares respectively, held directly.
Pulse Biosciences director and 10% owner Robert W. Duggan received two stock option grants on 08/15/2025 totaling 50,792 options to buy common stock at an exercise price of $16.16 per share. One option for 30,000 shares vests monthly over one year beginning 09/15/2025. The second option for 20,792 shares vests quarterly over one year beginning 09/05/2025. Both options expire 08/15/2035. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/19/2025.
Pulse Biosciences director Manmeet Singh was granted a stock option covering 30,000 shares of common stock with an exercise price of $16.16. The option was issued on 08/15/2025, is exercisable through 08/15/2035 and covers 30,000 underlying shares.
The option will vest in equal monthly installments over a one-year period, contingent on the reporting person’s continued service, with the first vesting installment occurring on September 15, 2025. The reporting person holds the option directly.
Pulse Biosciences, Inc. has called a virtual special stockholder meeting in September 2025 to vote on two equity compensation proposals. The first would amend the 2017 Equity Incentive Plan to add 2,000,000 shares of common stock for future awards and expand the definition of “Consultant” so equity can be granted to workers provided through third‑party employers of record.
The second proposal would ratify previously granted stock options under the plan to acquire up to 1,100,000 shares awarded in August 2024 and January 2025 to one executive, certain directors, and key clinical consultants, at exercise prices of $15.65 and $19.58 per share. As of August 2025, the company reports 67,283,347 shares of common stock outstanding, with major stockholder Robert W. Duggan beneficially owning 48,807,125 shares, or 72.3% of the class. The board unanimously recommends voting “FOR” both proposals.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
